Discuss Buspar in Our Community Forums
Buspar Side Effects Information
More Resources for Prescription Drugs
Complementary and Alternative Medicine
Herbal Medicine and Dietary Supplements
Buspar Description:
BuSpar is an anti-anxiety medication that is not chemically or pharmacologically
related to benzodiazepines, barbiturates, or other sedative/anxiolytic drugs.
Buspirone is commonly used to reduce fear, anxiety and tension associated
with common anxiety disorders. It is useful as an augmenting agent as well,
for treating depression when added to SSRIs.
Bristol-Myers Squibb gained approval from the FDA for Buspirone in 1986, and
the drug went generic in 2001.
Classification:
CLICK FOR RELATED CONTENT |
|
sedative-hypnotic
Clinical Pharmacology:
Buspirone’s mechanism of action is not known. BuSpar differs from typical
benzodiazepines in that it does not exhibit muscle-relaxing or anticonvulsant
effects. As well, it lacks the prominent sedative effect associated with other
anxiolytic drugs.
Pre-clinical studies have shown buspirone to have a high affinity for serotonin
receptors. It has no significant affinity for benzodiazepine receptors, but
has moderate affinity for dopamine receptors in the brain. Some studies do
suggest the drug may have indirect effects on other neurotransmitter systems.
Indications and Dosage:
BuSpar is indicated for the management of anxiety disorders or short-term
relief of anxiety symptoms, but not for anxiety or tension associated with
the stress of everyday life.
The recommended initial dose is 15mg per day (5mg 3 times a day). To reach
optimal therapeutic response, the dosage may be increased 5mg per day every
2 or 3 days, as needed. The maximum daily dosage should not exceed 60mg. In
clinical trials, divided dosages of 20 to 30mg/day were common.
Buspar Side Effects and Interactions:
Looking For a Non Prescription Solution? Click Here to Visit Our Marketplace.
Side effects are rarely dangerous or intense. Some tend to disappear with
continued use, or become less frequent if the initial dose is low and
gradually increased.
The most frequent side effects include vertigo, headache, agitation, nausea,
nervousness, light-headedness. Less frequent symptoms include insomnia, confusion,
depression, difficulty concentrating, drowsiness, intestinal disorders, paresthesia,
tremors, coordination disorders, tinnitus, disturbed visus, fatigue, weakness,
Angina pectoris, sore throat, tachycardias, palpitations, dry mouth, muscle
and joint pain.
Other, rare symptoms may include allergic reactions, subdermal bleeding, extrapyramidal
symptoms, tunnel vision, urine retention, alopecia, hallucinations, psychosis,
ataxia, epileptic seizures, syncope, pruritus, and urine retention. However,
the dyscognitive side effects of benzodiazepines are completely lacking.
Other side effects have been reported, but with no more frequency than those
encountered in placebo. An abnormal side effect reported has been an enhanced
sense of smell.
Drugs or substances that may interact with BuSpar include:
- Haloperidol – increased plasma-levels of Haloperidol
- Rifampizin – decreased
plasma-levels of Buspirone
- MAO-Inhibitors - severe hypertensive crises are
possible
- Alcohol
- Grapefruit/juice/extract – drastic increase in plasma-levels
of Buspirone
Information for Parents and Kids:
A recent pediatric study for BuSpar found that, while successful in treating
generalized anxiety disorder (GAD) in adults, was not helpful in treating certain
types of anxiety in children. Researchers say more testing is needed in order
to learn about the effects of these drugs on the immature brain.
Buspirone has not been studied in pregnant women, but has not been shown to
cause birth defects or other problems in animal studies. It is currently unknown
whether buspirone passes into human breast milk. The safety and efficacy of
buspirone is unknown in children under the age of 18.
Warnings and Precautions:
For people taking MAO Inhibitors, the addition of buspirone may pose a health
hazard. Reports of elevated blood pressure have occurred. It is therefore recommended
that buspirone not be used with an MAOI.
Buspirone has no established antipsychotic activity, and should not be used
in lieu of appropriate antipsychotic treatment. Studies have shown that buspirone
is less sedating that other anxiolytics and that it does not produce substantial
functional impairment. However, its effects on the central nervous system in
an individual may be unpredictable. Thus, patients should be cautioned about
operating automobiles or using complex machinery until they are sure the treatment
will not adversely affect them.
Withdrawal:
Because buspirone does not exhibit cross-tolerance with sedative/hypnotic
drugs such as benzodiazepines, it will not block the withdrawal syndrome often
seen when ceasing these types of medications.
The syndrome of withdrawal from sedatives, hypnotics, and anxiolytics can
appear as any combination of anxiety, insomnia, tremors, agitation, irritability,
abdominal cramping, muscle cramping, vomiting, flu-like symptoms (without fever),
sweating, and sometimes even seizures.
Over-dosage & Contraindications:
In clinical trials, doses as high as 375mg/day were administered to health
men. In approaching this dosage, symptoms such as nausea, dizziness, vomiting,
drowsiness, miosis, and gastric distress were seen. No deaths have been reported
in humans either with deliberate or accidental overdose of buspirone.
Contraindications with buspirone usage may include Myasthenia gravis (“grave
muscle weakness”), severely compromised liver- and renal-function, acute
closed-angle glaucoma, concomitant treatment with a MAOI (severe hypertensive
crises have been observed), and those with preexisting heart conditions (such
as myocardial infarction) should exercise caution.
Generic Name: Buspirone
Chemical Formula: C21H31N502
Routes of Administration: oral
Elimination Half Life: 2 to 3 hours
Legal Status: by prescription only
Join the Discussion:
Discuss Buspar and ask questions in our community forums
Recommended Links:
Sign up for our FREE Health and Wellness Newsletter
Buspirone Patient Instruction Sheet
FTC Press Release - Bristol-
Myers Squibb
View More Articles In
Category: Pharmaceuticals